References
- RayMKindlerHLMalignant pleural mesothelioma: an update on biomarkers and treatmentChest2009136388889619736192
- TetaMJMinkPJLauESceurmanBKFosterEDUS mesothelioma patterns 1973–2002: indicators of change and insights into background ratesEur J Cancer Prev200817652553418941374
- National Cancer Institute Surveillance Epidemiology, and End ResultsSEER*Stat software Available from: www.seer.cancer.gov/seerstatAccessed June 16, 2016
- MoolgavkarSHMezaRTurimJPleural and peritoneal mesotheliomas in SEER: age effects and temporal trends, 1973–2005Cancer Causes Control200920693594419294523
- RuschVWA proposed new international TNM staging system for malignant pleural mesothelioma from the International Mesothelioma Interest GroupLung Cancer19961411128696713
- Van SchilPMalignant pleural mesothelioma: staging systemsLung Cancer200549Suppl 1S45S4815950801
- CurranDSahmoudTTherassePvan MeerbeeckJPostmusPEGiacconeGPrognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experienceJ Clin Oncol19981611451529440736
- PotoskyALRileyGFLubitzJDMentnechRMKesslerLGPotential for cancer related health services research using a linked Medicare-tumor registry databaseMed Care19933187327488336512
- National Comprehensive Cancer NetworkNCCN guidelines for treatment of cancer by site: malignant pleural mesothelioma2015 Available from: https://www.nccn.org/professionals/physician_gls/f_guidelines.aspAccessed June 16, 2016
- JännePAFirst-line chemotherapy for malignant pleural mesotheliomaPassHIVogelzangNJCarboneMMalignant Mesothelioma: Advances in Pathogenesis, Diagnosis, and Translational TherapiesNew YorkSpringer2005593598
- MilanoMTZhangHMalignant pleural mesothelioma: a population-based study of survivalJ Thorac Oncol20105111841184820975379
- MeyerhoffRRYangCFSpeicherPJImpact of mesothelioma histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results databaseJ Surg Res20151961233225791825
- TaioliEWolfASMolineJMCamacho-RiveraMFloresRMFrequency of surgery in black patients with malignant pleural mesotheliomaDis Markers2015201528214526063951
- BlombergCNilssonJHolgerssonGRandomized trials of systemic medically-treated malignant mesothelioma: a systematic reviewAnticancer Res20153552493250125964522
- KrugLMWozniakAJKindlerHLRandomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesotheliomaLung Cancer201485342943425047675
- KindlerHLKarrisonTGGandaraDRMulticenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesotheliomaJ Clin Oncol201230202509251522665541
- VogelzangNJRusthovenJJSymanowskiJPhase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesotheliomaJ Clin Oncol200321142636264412860938
- MillensonMMLeeJHannaNHPemetrexed (Pem) plus gemcitabine (Gem) or carboplatin (Carbo) in patients (pts) with advanced malignant mesothelioma (MPM): a randomized phase II trial, E1B03J Clin Oncol20102815 Supple18053
- SzlosarekPWSteeleJPNolanLRandomized trial of arginine deprivation with pegylated arginine deiminase in patients with malignant pleural mesotheliomaJ Clin Oncol2014325 Suppl7507
- SamsonMKWasserLPBordenECRandomized comparison of cyclophosphamide, imidazole carboxamide, and adriamycin versus cyclophosphamide and adriamycin in patients with advanced stage malignant mesothelioma: a Sarcoma Intergroup studyJ Clin Oncol19875186913543239
- BuikhuisenWABurgersJAVincentADThalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 studyLancet Oncol201314654355123583604
- JassemJRamlauRSantoroAPhase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesotheliomaJ Clin Oncol200826101698170418375898
- ZalcmanGMazieresJMargeryJBevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed (MAPS): a randomized, controlled, open-label, phase 3 trialLancet2016387100261405141426719230
- Healthcaredeliverycancergov/[database on the Internet]Rockville, MDNational National Cancer Institute, Division of Cancer Control and Population Sciences Available from: http://healthcaredelivery.cancer.gov/seermedicare/obtain/use.htmlAccessed June 16, 2016